Phase I/II Clinical Trial of Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector) in Canada
Condition: COVID-19 Interventions: Biological: Recombinant Novel Coronavirus Vaccine (Adenovirus Type 5 Vector); Biological: Placebo Sponsors: CanSino Biologics Inc.; Beijing Institute of Biotechnology; Canadian Center for Vaccinology Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Adenoviruses | Biotechnology | Canada Health | Clinical Trials | Coronavirus | COVID-19 | Research | Vaccines